• 1
    Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997; 349: 15311536.
  • 2
    Cines DB,Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 9951008.
  • 3
    Beardsley DS. Pathophysiology of immune thrombocytopenic purpura. Blood Rev 2002; 16: 1314.
  • 4
    Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 912.
  • 5
    Chang M,Nakagawa PA,Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887895.
  • 6
    Mcmillan R,Wang L,Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 13641369.
  • 7
    Stasi R,Stipa E,Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436442.
  • 8
    Cohen YC,Djulbegovic B,Shamai-Lubovitz O,Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160: 16301638.
  • 9
    George JN,Woolf SH,Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American society of hematology. Blood 1996; 88: 340.
  • 10
    The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of the American society of hematology. Ann Intern Med 1997; 126: 319326.
  • 11
    Vianelli N,Galli M,De Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long-term results of 402 cases. Haematologica 2005; 90: 7277.
  • 12
    Zoghlami-Rintelen C,Weltermann A,Bittermann C, et al. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia. Ann Hematol 2003; 82: 290294.
  • 13
    Czuczman MS,Weaver R,Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 47114716.
  • 14
    Marcus R,Imrie K,Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 14171423.
  • 15
    Sehn LH,Donaldson J,Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 50275033.
  • 16
    O'brien SM,Kantarjian H,Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 21652170.
  • 17
    Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003; 22: 73597368.
  • 18
    Rastetter W,Molina A,White CA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55: 477503.
  • 19
    Stasi R,Pagano A,Stipa E,Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952957.
  • 20
    Saleh MN,Gutheil J,Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 27: 99103.
  • 21
    Cooper N,Stasi R,Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232239.
  • 22
    Bennett CM,Rogers ZR,Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 26392642.
  • 23
    Braendstrup P,Bjerrum OW,Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005; 78: 275280.
  • 24
    Garcia-Chavez J,Majluf-Cruz A,Montiel-Cervantes L, et al. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: A long-term follow-up analysis. Ann Hematol 2007; 86: 871877.
  • 25
    Penalver FJ,Jimenez-Yuste V,Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006; 85: 400406.
  • 26
    Godeau B,Porcher R,Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008; 112: 9991004.
  • 27
    Patel VMN,Cooper N,Stasi R, et al. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 Year. Blood 2006; 108: 1062.
  • 28
    Carson KR,Evens AM,Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 2009; 113: 48344840.
  • 29
    Zaja F,Battista ML,Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008; 93: 930933.
  • 30
    Fairweather H,Tuckfield A,Grigg A. Abbreviated dose rituximab for immune-mediated hematological disorders. Am J Hematol 2008; 83: 554557.
  • 31
    Mcmillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001; 344: 14021403.
  • 32
    Reiner A,Gernsheimer T,Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85: 351358.
  • 33
    Kuwana M,Iki S,Urabe A. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab. Am J Hematol 2007; 82: 846848.
  • 34
    Stasi R,Del Poeta G,Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 29242930.
  • 35
    Stasi R,Cooper N,Del Poeta G, et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 2008; 112: 11471150.
  • 36
    Zhao C,Li X,Zhang F,Wang L, et al. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008; 93: 14281430.
  • 37
    Olsson B,Andersson PO,Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 11231124.
  • 38
    Hainsworth JD,Litchy S,Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 10881095.